Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | DUT | P33316 | 1/20 | 0.44 |
| ▸ | TK2 | O00142 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | TK1 | P04183 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10554072 | 0.87 | USP2 (0.48) | KIF11DUTTK2CYP2C19KDM4E | |
| SCHEMBL10553963 | 0.87 | USP2 (0.48) | KIF11DUTTK2CYP2C19KDM4E | |
| SCHEMBL10553120 | 0.87 | USP2 (0.48) | KIF11DUTTK2CYP2C19KDM4E | |
| SCHEMBL10552104 | 0.87 | USP2 (0.48) | KIF11DUTTK2CYP2C19KDM4E | |
| SCHEMBL20829174 | 0.87 | CA1 (0.41) | KIF11DUTTK2CYP2C9ALOX15 | |
| SCHEMBL28645525 | 0.85 | CYP1A2 (0.50) | KIF11DUTTK2CYP2C9ALOX15 | |
| SCHEMBL28645526 | 0.85 | CYP1A2 (0.50) | KIF11DUTTK2CYP2C9ALOX15 | |
| SCHEMBL31430932 | 0.85 | KIF11 (0.65) | KIF11DUTTK2CYP2C9ALOX15 | |
| SCHEMBL26176912 | 0.85 | KIF11 (0.65) | KIF11DUTTK2CYP2C9ALOX15 | |
| SCHEMBL26176887 | 0.85 | KIF11 (0.65) | KIF11DUTTK2CYP2C9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20060198819-A1 | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2006-09-07 | — | — | US | disclosed |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| EP-1653996-A2 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | Novo Nordisk Health Care AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| EP-1654004-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005014035-A2 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTH CARE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014049-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060198819-A1 | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | GALE, GALNT2, GALNT1 | KIF11 3921/4885DUT 888/4885TK2 2417/4885 |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | VIP, PTMS, PDGFA | KIF11 1866/4885DUT 3475/4885TK2 3675/4885 |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | KIF11 1866/4885DUT 3475/4885TK2 3675/4885 |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | KIF11 3921/4885DUT 888/4885TK2 2417/4885 |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | INSR, IAPP, IGF1R | KIF11 903/4885DUT 4311/4885TK2 2820/4885 |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | KIF11 3921/4885DUT 888/4885TK2 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.